Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1Inflammation 1Hypertension 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Tumor Necrosis Factors × Clear all
NCT02743390 2017-11-09

Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension

University of Campinas, Brazil

Phase 4 Completed
10 enrolled

Hypertension, Inflammation

NCT00003789 2013-07-16

Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg

National Cancer Institute (NCI)

Phase 3 Completed
216 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡